Skip to main content

Table 1 Patients’ and host/donor characteristics

From: A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia

 

Haplo

MUD10/10

MMUD 9/10

MUD 10/10 vs Haplo

MMUD 9/10 vs Haplo

No.

265

2490

813

  

Follow-up

34.2 (3–84)

35.7 (1–103)

35.8 (1–102)

0.93

0.72

Age

42.8 (18–75)

47.0 (18–76)

44.8 (18–71)

<10–3

0.017

Year of Tx

2011 (07–13)

2010 (07–13)

2010 (07–13)

<10–3

<10–3

Diagnosis to transplant

260 days (82–5784)

196 days (71–5793)

223d (73–4452)

<10–3

0.016

Diagnosis

 AML

176

1645

510

  

66%

66%

63%

  

 ALL

89

845

303

0.90

0.28

34%

34%

37%

  

Disease status

 CR1

159

1901

580

  

60%

76%

71%

  

 CR2

106

589

233

<10–3

0.001

40%

24%

29%

  

Patient sex

 Male

155

1344

442

  

58%

54%

54%

  

 Female

110

1146

371

0.16

0.24

42%

46%

46%

  

Donor sex

 Male

139

1782

490

  

52%

72%

61%

  

 Female

126

690

312

<10–3

0.013

48%

28%

39%

  

Female to male

 No

191

2186

659

  

72%

88%

82%

  

 Yes

74

286

143

<10–3

<10–3

28%

12%

18%

  

CMV neg to neg

 No

225

1673

577

  

86%

69%

73%

  

 Yes

36

754

212

<10–3

<10–3

14%

31%

27%

  

Cytogenetics

 Good

29

261

68

  

11%

10%

8%

  

 Intermediate

168

1398

446

  

63%

56%

55%

  

 Poor

68

831

299

0.04

0.004

26%

33%

37%

  
  1. See text for abbreviations. Cytogenetic risk at diagnosis for AML: good t(8;21), inv16 or t(16;16); poor monosomy/deletion 5 or 7, abnormalities 11q23, complex karyotype (≥3 abnormalities); intermediate all the others. Cytogenetic risk at diagnosis for ALL: adverse t(9;22) or t(4;11), intermediate all the others